Znanstveni rad - Izvorni znanstveni rad
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes & Endocrinology, 7 (2019), 8; 618-628. https://doi.org/10.1016/s2213-8587(19)30158-5

Ray, Kausik K.; Colhoun, Helen M.; Szarek, Michael; Baccara-Dinet, Marie; Bhatt, Deepak L.; Bittner, Vera A.; Budaj, Andrzej J.; Diaz, Rafael; Goodman, Shaun G et all.; Reiner, Željko; Peršić, Viktor

Citirajte ovaj rad

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara Dinet, M., Bhatt, D. L., Bittner, V. A. ... Peršić, V. (2019). Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet Diabetes & Endocrinology, 7. (8), 618-628. doi: 10.1016/s2213-8587(19)30158-5

Ray, Kausik K., et al. "Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial." The Lancet Diabetes & Endocrinology, vol. 7, br. 8, 2019, str. 618-628. https://doi.org/10.1016/s2213-8587(19)30158-5

Ray, Kausik K., Helen M. Colhoun, Michael Szarek, Marie Baccara Dinet, Deepak L. Bhatt, Vera A. Bittner, Andrzej J. Budaj, et al. "Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial." The Lancet Diabetes & Endocrinology 7, br. 8 (2019): 618-628. https://doi.org/10.1016/s2213-8587(19)30158-5

Ray, K. K., et al. (2019) 'Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial', The Lancet Diabetes & Endocrinology, 7(8), str. 618-628. doi: 10.1016/s2213-8587(19)30158-5

Ray KK, Colhoun HM, Szarek M, Baccara Dinet M, Bhatt DL, Bittner VA, i sur.. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet Diabetes & Endocrinology [Internet]. 2019. [pristupljeno 07.07.2024.];7(8):618-628. doi: 10.1016/s2213-8587(19)30158-5

K. K. Ray, et al., "Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial", The Lancet Diabetes & Endocrinology, vol. 7, br. 8, str. 618-628, 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:784502. [Citirano: 07.07.2024.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.